Forte Biosciences Shares Fall 7.5% Premarket as FB102 Delivers 29.6% Vitiligo Gains
FBRX•Forte Biosciences’ FB102 phase 1b vitiligo trial produced a 29.6% mean FVASI improvement from baseline at week 24 (p=0.020), with significant response as early as day 64 (p=0.023). Its shares dropped 7.5% in premarket trading ahead of the open.
1. Premarket Stock Movement
Forte Biosciences’ shares fell 7.51% in premarket trading on July 9, underperforming peers despite positive clinical data. The drop suggests investor caution ahead of broader market open and further company updates.
2. FB102 Phase 1b Trial Results
In a double-blind placebo-controlled phase 1b study, FB102 achieved a mean 29.6% reduction in Facial Vitiligo Area Severity Index (FVASI) from baseline at week 24 (p=0.020). Statistically significant improvements were noted by day 64 (p=0.023), indicating early onset of therapeutic effect.
3. Clinical and Commercial Implications
The positive vitiligo data support advancement to larger trials and strengthen Forte’s autoimmune pipeline. Future studies will determine optimal dosing, long-term safety and potential market positioning for FB102 as a novel vitiligo therapy.
